FemiLift for Menopause-Related Vaginal Dryness in Philadelphia: What Patients Should Know

Menopause can bring physical changes that are rarely discussed openly. Vaginal dryness, irritation, discomfort during intimacy, urinary urgency, and reduced tissue elasticity may affect daily comfort, relationships, confidence, and quality of life.

These symptoms are common, but patients should not assume they must simply tolerate them. Several treatment options are available, ranging from vaginal moisturizers and prescription therapies to energy-based procedures such as FemiLift.

For patients researching FemiLift for vaginal dryness in Philadelphia, it is important to understand how the treatment works, what it may involve, its limitations, potential risks, and how it compares with established menopause treatments.

Philly FemiLift offers consultations through the Pennsylvania Centre for Plastic Surgery, with locations in Philadelphia and Plymouth Meeting, Pennsylvania. Each patient should receive an individual evaluation before deciding whether FemiLift or another treatment is appropriate.

Why Does Vaginal Dryness Happen During Menopause?

Menopause is reached after a person has gone 12 consecutive months without a menstrual period. It usually occurs between ages 45 and 55, although the timing varies.

During perimenopause and menopause, the ovaries gradually produce less estrogen. Estrogen helps maintain the thickness, moisture, blood supply, flexibility, and overall health of vaginal and vulvar tissues.

As estrogen levels decline, the tissues may become thinner, drier, less elastic, and more sensitive. These changes can contribute to discomfort during daily activities and sexual intimacy.

What Is Genitourinary Syndrome of Menopause?

The group of vaginal, vulvar, sexual, and urinary symptoms associated with lower estrogen levels is commonly called genitourinary syndrome of menopause, or GSM.

Unlike some symptoms of menopause that may improve over time, GSM symptoms can continue or become more noticeable without appropriate management.

Common symptoms may include:

• Vaginal dryness
• Burning or irritation
• Discomfort during intercourse
• Reduced natural lubrication
• Vulvar discomfort
• Urinary urgency
• Frequent urination
• Recurrent urinary tract infections
• Mild urinary leakage
• Changes in sexual comfort

These symptoms can also be caused by infections, skin conditions, medication effects, pelvic-floor disorders, and other medical concerns. A professional examination is important before symptoms are attributed to menopause.

What Is FemiLift?

FemiLift is an energy-based treatment platform developed by Alma Lasers. It uses fractional carbon dioxide, or CO₂, laser technology delivered through specialized applicators.

During treatment, fractional laser energy creates controlled microscopic treatment zones within the selected tissue. The surrounding tissue remains untreated, which is intended to support the tissue-response and recovery process.

The manufacturer describes FemiLift as a minimally invasive, outpatient procedure used in feminine-wellness and gynecological applications. Its fractional laser beam is divided into multiple microscopic pixels to create controlled ablative and thermal zones.

FemiLift treatment does not involve traditional surgical incisions or general anesthesia. However, it is still a medical laser procedure and should only be performed after an appropriate examination and informed discussion with a qualified provider.

How Is FemiLift Intended to Work?

FemiLift delivers fractional CO₂ laser energy to the treatment area. The controlled thermal effect is intended to stimulate a tissue-healing response and collagen remodeling.

Collagen contributes to tissue structure and elasticity. The manufacturer promotes FemiLift for feminine-wellness concerns associated with hormonal changes, aging, childbirth, and other life events.

Patients should understand that biological response, symptom improvement, treatment comfort, and recovery vary. FemiLift should not be presented as a guaranteed cure for vaginal dryness, urinary leakage, sexual discomfort, or other symptoms.

Is FemiLift FDA-Approved for Menopause Symptoms?

This distinction is important.

FemiLift and similar laser systems may be cleared for certain medical and gynecological uses, but energy-based devices have not been specifically FDA-cleared or approved to treat genitourinary syndrome of menopause, vaginal dryness, urinary incontinence, sexual dysfunction, or for cosmetic vaginal “rejuvenation.”

The Menopause Society states that vaginal lasers may be cleared for vaginal use, but not specifically for the treatment of GSM. It also notes that current evidence does not support routinely using these treatments for vaginal dryness, irritation, urinary discomfort, pain during intercourse, or quality-of-life improvement.

For patients who cannot use or prefer alternatives to government-approved therapies, fractional CO₂ laser treatment may be discussed through shared decision-making, with the understanding that it remains experimental for GSM outside clinical research.

The American College of Obstetricians and Gynecologists also advises patients that high-quality evidence remains limited and that energy-based vaginal treatments may carry risks such as burns, scarring, pain during intercourse, altered sensation, and persistent pain.

A compliant consultation should clearly explain this regulatory status rather than describing FemiLift as FDA-approved specifically for menopause-related vaginal dryness.

Who May Consider a FemiLift Consultation?

A consultation may be considered by adults experiencing concerns such as dryness, irritation, discomfort during intimacy, changes following childbirth, or other feminine-wellness symptoms.

A potential patient may be interested in FemiLift when she:

• Is experiencing vaginal or vulvar discomfort
• Wants to discuss non-surgical treatment options
• Cannot use certain hormonal therapies
• Has not achieved enough relief from basic moisturizers or lubricants
• Understands that evidence for laser treatment of GSM remains limited
• Has realistic expectations
• Is willing to complete an examination before treatment
• Understands possible risks and alternative options

Interest in treatment does not automatically mean someone is an appropriate candidate. The cause of the symptoms must first be evaluated.

Who May Not Be an Appropriate Candidate?

A provider should review the patient’s complete medical and gynecological history before treatment.

Important information may include:

• Pregnancy or possible pregnancy
• Active vaginal, urinary, or sexually transmitted infection
• Unexplained vaginal bleeding
• Abnormal Pap test results
• Pelvic pain without a diagnosis
• Open wounds or active skin conditions
• Recent gynecological surgery
• Pelvic organ prolapse
• History of radiation treatment
• Blood-clotting disorders
• Immune-system conditions
• Use of medications that affect healing
• Previous reactions to laser procedures

The FemiLift manufacturer recommends a gynecological examination, including appropriate cervical screening, before treatment.

Any bleeding after menopause should be medically evaluated before a cosmetic or wellness procedure is considered.

What Happens During a FemiLift Consultation?

The consultation should begin with a discussion of the patient’s symptoms, medical history, menopause status, previous treatments, medications, and personal goals.

The provider may ask:

• When did the symptoms begin?
• Is dryness present every day or mainly during intimacy?
• Is there burning, itching, discharge, or odor?
• Has there been any unexpected bleeding?
• Are urinary symptoms also present?
• Have lubricants or moisturizers been tried?
• Is the patient currently using vaginal or systemic hormones?
• Is there a personal history of breast or uterine cancer?
• Have there been previous pelvic procedures?

The purpose of this discussion is not simply to sell a procedure. It is to determine whether the symptoms are likely related to menopause or whether an infection, skin condition, pelvic-floor problem, or another medical issue needs treatment.

What to Expect During Treatment

The exact experience depends on the device settings, applicator, treatment area, and individual plan.

A typical appointment may include:

Treatment Preparation

The patient is positioned comfortably, and the treatment area is prepared according to clinical protocol.

Applicator Placement

A specialized applicator is carefully positioned. Fractional CO₂ laser energy is then delivered in a controlled pattern.

Treatment Sensation

The manufacturer describes the procedure as relatively fast, with possible mild discomfort. Experiences vary, and patients should communicate any unexpected pain during the session.

Completion and Instructions

After treatment, the provider should review activity restrictions, hygiene guidance, expected temporary symptoms, and warning signs that require medical attention.

How Many FemiLift Treatments May Be Recommended?

The FemiLift manufacturer states that an initial series of approximately two to three treatments may be recommended, depending on the patient’s symptoms and their severity.

This is not a universal schedule or a guarantee of results. The number of sessions may be influenced by:

• Type and severity of symptoms
• Tissue condition
• Age and menopause status
• Previous treatments
• Medical history
• Treatment response
• Provider protocol

Some practices may also discuss future maintenance treatments. Patients should ask what evidence supports the recommended schedule and what total cost may be involved.

What Is Recovery Like?

FemiLift is generally performed in an outpatient setting. The manufacturer states that patients may return to their normal routine relatively quickly, but individual post-treatment instructions can vary.

Temporary effects may include:

• Mild tenderness
• Warmth
• Spotting
• Watery discharge
• Swelling
• Irritation
• Sensitivity

Patients may be instructed to avoid intercourse, tampons, hot baths, swimming, and strenuous exercise for a specific period.

The treating provider’s written instructions should always take priority over general online advice.

Contact the clinic promptly if you experience severe pain, heavy bleeding, fever, foul-smelling discharge, difficulty urinating, worsening swelling, or symptoms that do not improve as expected.

Other Treatments for Menopause-Related Vaginal Dryness

FemiLift is not the only option, and it should not automatically be the first treatment considered.

Vaginal Lubricants

Lubricants are used during intimacy to reduce friction and discomfort. They provide temporary relief but do not continuously moisturize vaginal tissues.

Vaginal Moisturizers

Moisturizers are used regularly rather than only during sexual activity. They can help maintain moisture and reduce everyday dryness.

Low-Dose Vaginal Estrogen

Vaginal estrogen is available in creams, tablets, inserts, and rings. It can help rebuild and moisturize tissues affected by low estrogen levels.

The Menopause Society identifies low-dose vaginal estrogen as an established and effective option for GSM. It generally results in much lower systemic absorption than systemic hormone therapy.

Vaginal DHEA

Prasterone is a prescription vaginal insert that may be used for vaginal dryness and pain during intercourse related to menopause.

Ospemifene

Ospemifene is a prescription oral medication used for certain menopause-related vulvar and vaginal symptoms.

Pelvic-Floor Therapy

Pain during intimacy, urinary leakage, or pelvic discomfort may also involve pelvic-floor muscle tension, weakness, or coordination problems. Pelvic-floor physical therapy may be appropriate for some patients.

The right treatment depends on symptoms, medical history, breast-cancer risk, hormone preferences, previous response, cost, and personal values.

FemiLift vs. Hormonal Treatment

FemiLift and vaginal hormone therapy work in different ways.

Low-dose vaginal estrogen directly addresses the low-estrogen environment responsible for many GSM symptoms. It has stronger established evidence for vaginal dryness and related discomfort.

FemiLift uses fractional laser energy and does not administer hormones. This may make it appealing to people seeking a nonhormonal option, but “nonhormonal” does not automatically mean risk-free or medically superior.

Patients who have a history of hormone-sensitive cancer should discuss vaginal dryness with their gynecologist and oncology team. Decisions about low-dose hormones or alternative treatments should be made through individualized shared decision-making.

Questions to Ask Before Choosing FemiLift

Before scheduling treatment, consider asking:

• What is causing my symptoms?
• Have infection and other medical conditions been ruled out?
• Is FemiLift specifically cleared for my diagnosis?
• What evidence supports its use for my symptoms?
• What established treatments should I consider first?
• What side effects and complications are possible?
• How many sessions are recommended?
• What is the complete cost?
• What happens if my symptoms do not improve?
• How long should I avoid intercourse or exercise?
• Who will perform the procedure?
• What training and experience does the provider have?
• How are complications managed?

Clear answers help patients make informed decisions without relying on unrealistic promises.

Why Choose Philly FemiLift?

Philly FemiLift is associated with the Pennsylvania Centre for Plastic Surgery and offers access to consultations in Philadelphia and Plymouth Meeting.

Current official practice information lists:

Philadelphia Office
822 Pine Street, Suite 3B
Philadelphia, PA 19107

Plymouth Meeting Office
531 W. Germantown Pike, Suite 100
Plymouth Meeting, PA 19462

Patients can contact the practice at 267-687-2180 to request a consultation.

Schedule a FemiLift Consultation in Philadelphia

Menopause-related vaginal dryness is common, but it should not be ignored when it affects comfort, intimacy, urinary health, or quality of life.

FemiLift offers a fractional CO₂ laser-based approach that some patients may wish to explore. However, it is essential to understand that energy-based devices are not specifically FDA-cleared or approved for treating GSM, menopause-related vaginal dryness, urinary incontinence, or sexual dysfunction.

A responsible consultation should include a proper examination, discussion of established treatments, review of the available evidence, clear explanation of risks, and realistic expectations.

Contact Philly FemiLift to schedule a private consultation in Philadelphia or Plymouth Meeting and discuss which feminine-wellness treatment may be most appropriate for your symptoms and medical history.

Individual experiences and outcomes vary. This article is for general educational purposes and does not replace personalized medical advice, diagnosis, or treatment from a qualified healthcare professional.